Discover and read the best of Twitter Threads about #ash21vr
Most recents (3)
Here are my Top 5 #ASCO22 @ASCO myeloma abstracts. #ASCO22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
#5 Risk adapted maintenance: Len for standard risk & Len plus Bortezomib for high risk gives outstanding results. #ASCO22 #ASCO22VR
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
Besides my Top 5 picks in myeloma at #ASH21 listed below the 3 most important findings being presented in myeloma this year are:
1) A variety of bispecifics showing high single agent activity
2) CAR-T efficacy
3) PFS improvement with Dara-VRd in GRIFFIN
#ASH21VR
1) A variety of bispecifics showing high single agent activity
2) CAR-T efficacy
3) PFS improvement with Dara-VRd in GRIFFIN
#ASH21VR
Bispecifics and CART single agent activity is more than double of the single agent activity seen with existing drugs. Slide from @TomBmt133 #ASH21 
Cilta-cel efficacy presented by @TomBmt133 is also outstanding and well summarized in this tweet by @ninashah33 #ASH21
Here are my Top 5 #ASH21 @ASH_hematology myeloma abstracts. #ASH21VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
#5 Outcome of patients with refractory myeloma treated with bispecific antibodies.
64 patients. Median 7 prior regimens. 58% response rate. Importantly median survival 18 months — brings hope. @tarekmd91 @JoshuaRichterMD @MountSinaiNYC #ASH21 #ASH21VR ash.confex.com/ash/2021/webpr…
64 patients. Median 7 prior regimens. 58% response rate. Importantly median survival 18 months — brings hope. @tarekmd91 @JoshuaRichterMD @MountSinaiNYC #ASH21 #ASH21VR ash.confex.com/ash/2021/webpr…
#4 Prevalence of smoldering myeloma (SMM) in the general population.
75,000 person RCT iStopMM estimates prevalence at 0.5% of population age >=40 #ASH21 #ASH21VR @SigrunThorstei1 @sykristinsson @DrOlaLandgren @TBSsteharding @BrianDurieMD @MalinHultcrantz ash.confex.com/ash/2021/webpr…
75,000 person RCT iStopMM estimates prevalence at 0.5% of population age >=40 #ASH21 #ASH21VR @SigrunThorstei1 @sykristinsson @DrOlaLandgren @TBSsteharding @BrianDurieMD @MalinHultcrantz ash.confex.com/ash/2021/webpr…
